Ichnos Sciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ichnos Sciences sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Ichnos Sciences: 7 sponsored US clinical trials, 1 recruiting.
Ichnos Sciences sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Relapsed/Refractory Multiple Myeloma, with 1 trials.
Upper-quartile sponsor footprint
Ichnos Sciences sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
NCT05862012
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
NCT05427812
Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer
NCT03983395
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
NCT03568162
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
NCT03309111
Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers
NCT02829372
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis
NCT02683928
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Ichnos Sciences pipeline
1 recruiting of 7 indexed (14% open); 3 completed (43%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Relapsed/Refractory Multiple Myeloma (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ichnos Sciences: open-pipeline peers nationwide
Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Ichnos Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Ichnos Sciences page
7 registered trials is a research-attention snapshot, not an endorsement of Ichnos Sciences or any single study.
- 1 of Ichnos Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Relapsed/Refractory Multiple Myeloma is the condition Ichnos Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Relapsed/Refractory Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ichnos Sciences pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.